Platform
A smarter way to
deliver mRNA
Navibody mRNA therapeutics delivery platform
An mRNA delivery platform that enhances antibody–LNP specificity and boosts production efficiency.
Why targeted Delivery matters
Since the COVID-19 pandemic in 2020, mRNA technology has transformed the global vaccine market.
Its potential now extends beyond infectious diseases to genetic disorders, oncology, and personalized therapies.
Yet without reaching target cells precisely, much of that potential remains untapped.
Precision targeting is the next breakthrough for mRNA therapeutics.
Why it works better
Enhanced targeting of mRNA–LNP
Significantly improves targeting of mRNA–LNP therapeutics, enabling in vivo administration.
Minimized off-target effects
Reduces off-target delivery to organs such as the liver and spleen.
A versatile targeted delivery platform
Navibody technology allows broad applications through diverse combinations of antibodies and mRNA.
Navibody Platform
Navibody (Navigation Antibody) is a fusion of an LNP-binding protein and an antibody. It stably attaches to an mRNA–LNP (an LNP encapsulating an mRNA therapeutic) and enables precise delivery down to the cellular level of the target organ.
mRNA(messenger RNA)
mRNA is a type of RNA molecule that carries genetic information from DNA to ribosomes, where proteins are synthesized. It serves as a blueprint, directing cells to produce specific proteins, and is an essential mediator of genetic information transfer.
LNP(Lipid Nanoparticle)
LNPs are delivery carriers that transport mRNA vaccines or therapeutics safely and efficiently into cells. They act as a protective shield that prevents unstable mRNA from degrading and enables its entry into cells. Once their job is done, LNPs naturally break down inside the body.
Structure of Navibody
mRNA–LNP therapeutic with Navibody attached
Efforts of improving mRNA delivery
LNP-based therapeutics in their early stage were delivered mostly to the liver as an unintended outcome, limiting their broader application. They have since evolved into precision delivery technologies that can reach diverse organs and specific cells. MVRIX enables safe and accurate delivery at the cellular level.
History of Targeted mRNA Delivery
The first generation of mRNA–LNP therapeutics
LNPs are fast to develop and safe, making them valuable as vaccine carriers. However, when administered systemically, most are absorbed by the liver, which can limit therapeutic efficacy or cause unwanted side effects.
Chemical conjugation vs. One-step self-assembly
Chemical conjugation
One-step self-assembly
Platform expansion
The Navibody platform offers broad applicability in therapeutic development, combining versatility, stability, and scalability.
Applications of the Navibody Platform
Pipeline MGB-p53
mRNA targeted Cancer delivery
It delivers mRNA that suppresses cancer cells directly to tumor cells, increasing therapeutic efficiency and reducing side effects from off-target delivery.
Cancer Vaccine
By activating immune cells to attack tumors, it can be applied to both cancer prevention and treatment.
Radiation Therapy
It can enhance the effectiveness of radiation therapy.
Chemotherapy and Immunotherapy
It can guide the tumor microenvironment to respond more effectively to chemotherapy and immunotherapy.
Mechanism of action of MGB-P53
Healthy cell
HER2-overexpressed cancer cell
POC : MGB-P53
As a proof of concept for the Navibody platform, MVRIX combined Trastuzumab as the antibody component and P53 as the mRNA payload, creating the candidate MGB-P53.
p53
p53 functions as a tumor suppressor and is found mutated in nearly all cancers. Its coding gene, TP53, is among the most extensively studied genes, cited in over 10,000 publications since its discovery in 1979.
HER2 target and p53 gene with complementary roles
Expression of p53 and HER2
p53 mutations induce overexpression of HER2
Cancer Cell Targeting Validation
Cancer cell targeting validation of MGB-P53
3x higher delivery, 7x higher mRNA expression
Functionality Validation(Cancer cell killing effect)
Administration of MGB-P53 resulted in a reduction in both tumor volume and weight
R&D Achievements
Discover the intellectual property activities we are pursuing around Navibody.
Filed
PCT
7/1/25
P53 단백질을 암호화하는 mRNA가 탑재되어 있는 HER2 결합 지질나노입자를 함유하는 약학 조성물
Filed
PCT
7/1/25
표적 전달능 및 안전성이 개선된 지질나노입자 약학 조성물
Filed
KR
6/30/25
표적 전달능 및 안전성이 개선된 지질나노입자 약학 조성물
Filed
KR
6/25/25
mRNA 지질나노입자 기반 in vivo CAR-T 기술을 이용한 자가면역치료제
Filed
KR
6/25/25
mRNA 지질나노입자 기반 in vivo CAR-T 기술을 이용한 림프구성 혈액암 치료제
Filed
KR
5/11/25
암과 수지암과 수지상세포에 항원을 동시 전달할 수 있는 지질나노입자 및 이를 함유하는 항암 조성물
Filed
KR
3/30/25
클러스테린이 융합된 항체 및 이 항체가 자기결합하여 형성된 항체결합 지질나노입자
Filed
CN
8/29/24
Antibody-binding lipid nanoparticles comprising antibodies bound to membrane scaffold proteins
Filed
IN
8/26/24
Antibody-binding lipid nanoparticle with antibody bound to membrane scaffold protein
Filed
EU
8/18/24
Antibody-bound lipid nanoparticle comprising antibody bound to membrane scaffold protein
Filed
US
7/26/24
Antibody-bound lipid nanoparticle comprising antibody bound to membrane scaffold protein
Filed
JP
7/25/24
Antibody-binding lipid nanoparticle with antibody bound to membrane scaffold protein
Filed
KR
7/2/24
p53 단백질을 암호화하는 mRNA가 탑재되어 있는 HER2 결합 지질나노입자를 함유하는 약학 조성물
Filed
PCT
1/26/23
Antibody-bound lipid nanoparticle comprising antibody bound to membrane scaffold protein
10-2698524
KR
8/20/24
Antibody-binding lipid nanoparticle with antibody bound to membrane scaffold protein
10-1647178
KR
8/3/16
Stabilized Plasmid-Lipid Particles Using polyethylen glycol-lipid composed of an Enzymatically Cleavable Linker or oligo-lysines